Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.nuvectis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2022 | $21.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $14.00 | Buy | HC Wainwright & Co. |
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00
HC Wainwright & Co. initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $14.00
Cleveland Clinic research provides further positive validation Nuvectis Pharma's* NXP900 cancer-fighting potential, showing enhanced efficacy when combined with AstraZeneca's blockbuster drug Tagrisso® in EGFR+ lung cancer models. New $18 price target and buy recommendation from Lucid Capital Markets implies 200%+ potential upside as Phase 1b trial approaches Market News Alerts Reports: Nuvectis Pharma (NASDAQ:NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cance
Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a new publication from the laboratory of Prof. Ruth Keri, (Cleveland Clinic, Cleveland, OH, USA) demonstrating that the combination of NXP900 and osimertinib (the active ingredient in Tagrisso®) was superior to single agent osimertinib in vivo in a model of Epidermal Growth Factor Receptor(EGFR) mutated non-small cell lung cancer (NSCLC), and led to decreased cell proliferation and i
Precision oncology player Nuvectis Pharma receives a buy recommendation and price target with a significant premium from Lucid Capital Markets. Report highlights Nuvectis' potential to generate hundreds of millions of dollars in revenue and notes upcoming phase 1a clinical data as a potential catalyst Market News Alerts Reports: Lucid Capital Markets has initiated coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Buy rating and a price target of $18. The firm's report highlights Nuvectis' promising oncology pipeline, particularly its lead asset, NXP900, a SRC/YES1 inhibitor targeting squamous cell carcinomas with high unmet need. Lucid's report emphasizes the strong potential of NXP900,
NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025NXP900 Phase 1a dose escalation study continues to enroll, preparation for the start of the Phase 1b program is underway. Phase 1b program expected to begin in mid-2025Follow-on offering completed in February 2025 extends cash runway into 2027 FORT LEE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious condit
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock, and the exercise in full of the underwriter's option to purchase 405,000 additional shares. The common stock shares were offered at a price of $5.00 per share, resulting in gross proceeds to Nuvectis of approximately $15.5 million, before deducting underwriting discounts and commissions. Lucid Capital Mark
FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the pricing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price of $5.00 per share, with expected gross proceeds to Nuvectis of $13.5 million. Nuvectis has also granted the underwriter a 30-day option to purchase up to 405,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expe
FORT LEE, NJ, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Nuvectis. In addition, Nuvectis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to wh
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDate12 December 2024Time10 am EST About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicin
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis.
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter
10-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)
S-8 - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)